Listed

Telomir Pharmaceuticals, Inc.

TELONasdaqCIK 1971532HealthcareFiscal year ends Dec 31

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Operating income$2.2m, Q1 FY2025
Net income−$1.7m, Q2 FY2026
Telomir Pharmaceuticals, Inc., income statement, quarterly
Line itemUnitperiod not labelled2023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Research and development$k263Research and development, period not labelled, three months to 2023-09-30$262.6k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2024-11-12, accession 0001493152-24-044749.Report this figure204Research and development, Q4 FY2023, three months to 2023-12-31$203.8k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2025-02-04, accession 0001493152-25-004872. Derived: 12-month figure less the 9-month figure.Report this figure804Research and development, Q1 FY2024, three months to 2024-03-31$804.0k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-05-14, accession 0001641172-25-010298.Report this figure595Research and development, Q2 FY2024, three months to 2024-06-30$594.8k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-08-14, accession 0001641172-25-023970.Report this figure627Research and development, Q3 FY2024, three months to 2024-09-30$627.4k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-10, accession 0001493152-25-021496.Report this figure269Research and development, Q4 FY2024, three months to 2024-12-31$269.1k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-03-17, accession 0001493152-26-010625. Derived: 12-month figure less the 9-month figure.Report this figure337Research and development, Q1 FY2025, three months to 2025-03-31$337.0k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-14, accession 0001493152-26-023010.Report this figure42.8Research and development, Q2 FY2025, three months to 2025-06-30$42.8k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-13, accession 0001493152-26-037854.Report this figure760Research and development, Q3 FY2025, three months to 2025-09-30$759.5k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-10, accession 0001493152-25-021496.Report this figure1,296Research and development, Q4 FY2025, three months to 2025-12-31$1.3m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-03-17, accession 0001493152-26-010625. Derived: 12-month figure less the 9-month figure.Report this figure468Research and development, Q1 FY2026, three months to 2026-03-31$467.8k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-14, accession 0001493152-26-023010.Report this figure445Research and development, Q2 FY2026, three months to 2026-06-30$444.7k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-13, accession 0001493152-26-037854.Report this figure
Operating income$knot reportednot reported1,916Operating income, Q1 FY2024, three months to 2024-03-31$1.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-05-14, accession 0001641172-25-010298.Report this figurenot reportednot reportednot reported2,188Operating income, Q1 FY2025, three months to 2025-03-31$2.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-05-14, accession 0001641172-25-010298.Report this figurenot reportednot reportednot reportednot reportednot reported
Interest expense$k757Interest expense, period not labelled, three months to 2023-09-30$757.2k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2024-11-12, accession 0001493152-24-044749.Report this figure762Interest expense, Q4 FY2023, three months to 2023-12-31$761.8k. XBRL concept us-gaap:InterestExpense. 10-K filed 2024-03-29, accession 0001493152-24-012049. Derived: 12-month figure less the 9-month figure.Report this figure4,339Interest expense, Q1 FY2024, three months to 2024-03-31$4.3m. XBRL concept us-gaap:InterestExpense. 10-Q filed 2024-05-13, accession 0001493152-24-018909.Report this figure(0.0)Interest expense, Q2 FY2024, three months to 2024-06-30−$1. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2025-08-14, accession 0001641172-25-023970. Derived: 6-month figure less the 3-month figure.Report this figure0.0Interest expense, Q3 FY2024, three months to 2024-09-30$1. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2025-11-10, accession 0001493152-25-021496. Derived: 9-month figure less the 6-month figure.Report this figure(0.0)Interest expense, Q4 FY2024, three months to 2024-12-31−$1. XBRL concept us-gaap:InterestExpenseNonoperating. 10-K filed 2026-03-17, accession 0001493152-26-010625. Derived: 12-month figure less the 9-month figure.Report this figure0.0Interest expense, Q1 FY2025, three months to 2025-03-31$46. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2026-05-14, accession 0001493152-26-023010.Report this figure1.3Interest expense, Q2 FY2025, three months to 2025-06-30$1.3k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2026-08-13, accession 0001493152-26-037854.Report this figure0.0Interest expense, Q3 FY2025, three months to 2025-09-30$0. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2025-11-10, accession 0001493152-25-021496. Derived: 9-month figure less the 6-month figure.Report this figurenot reported1.3Interest expense, Q1 FY2026, three months to 2026-03-31$1.3k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2026-05-14, accession 0001493152-26-023010.Report this figure3.0Interest expense, Q2 FY2026, three months to 2026-06-30$3.0k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2026-08-13, accession 0001493152-26-037854.Report this figure
Net income$k(1,711)Net income, period not labelled, three months to 2023-09-30−$1.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2024-11-12, accession 0001493152-24-044749.Report this figure(9,327)Net income, Q4 FY2023, three months to 2023-12-31−$9.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2024-05-13, accession 0001493152-24-018909.Report this figure(6,255)Net income, Q1 FY2024, three months to 2024-03-31−$6.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-10, accession 0001493152-25-021496.Report this figure(1,389)Net income, Q2 FY2024, three months to 2024-06-30−$1.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-10, accession 0001493152-25-021496.Report this figure(5,991)Net income, Q3 FY2024, three months to 2024-09-30−$6.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-10, accession 0001493152-25-021496.Report this figure(2,898)Net income, Q4 FY2024, three months to 2024-12-31−$2.9m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-17, accession 0001493152-26-010625. Derived: 12-month figure less the 9-month figure.Report this figure(2,180)Net income, Q1 FY2025, three months to 2025-03-31−$2.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-14, accession 0001493152-26-023010.Report this figure(5,070)Net income, Q2 FY2025, three months to 2025-06-30−$5.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-13, accession 0001493152-26-037854.Report this figure(1,102)Net income, Q3 FY2025, three months to 2025-09-30−$1.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-10, accession 0001493152-25-021496.Report this figure(2,061)Net income, Q4 FY2025, three months to 2025-12-31−$2.1m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-17, accession 0001493152-26-010625. Derived: 12-month figure less the 9-month figure.Report this figure(991)Net income, Q1 FY2026, three months to 2026-03-31−$990.9k. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-13, accession 0001493152-26-037854.Report this figure(1,722)Net income, Q2 FY2026, three months to 2026-06-30−$1.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-13, accession 0001493152-26-037854.Report this figure
Diluted EPS$ per share(0.06)Diluted EPS, period not labelled, three months to 2023-09-30−$0.06 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2024-11-12, accession 0001493152-24-044749.Report this figurenot reported(0.23)Diluted EPS, Q1 FY2024, three months to 2024-03-31−$0.23 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-05-14, accession 0001641172-25-010298.Report this figure0.05Diluted EPS, Q2 FY2024, three months to 2024-06-30$0.05 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-08-14, accession 0001641172-25-023970.Report this figure(0.20)Diluted EPS, Q3 FY2024, three months to 2024-09-30−$0.20 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-10, accession 0001493152-25-021496.Report this figurenot reported(0.07)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$0.07 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-14, accession 0001493152-26-023010.Report this figure(0.17)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$0.17 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-13, accession 0001493152-26-037854.Report this figure(0.03)Diluted EPS, Q3 FY2025, three months to 2025-09-30−$0.03 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-10, accession 0001493152-25-021496.Report this figurenot reported(0.03)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$0.03 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-14, accession 0001493152-26-023010.Report this figure(0.79)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$0.79 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-13, accession 0001493152-26-037854.Report this figure
Basic EPS$ per share(0.06)Basic EPS, period not labelled, three months to 2023-09-30−$0.06 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2024-11-12, accession 0001493152-24-044749.Report this figurenot reported(0.23)Basic EPS, Q1 FY2024, three months to 2024-03-31−$0.23 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-05-14, accession 0001641172-25-010298.Report this figure0.05Basic EPS, Q2 FY2024, three months to 2024-06-30$0.05 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-08-14, accession 0001641172-25-023970.Report this figure(0.20)Basic EPS, Q3 FY2024, three months to 2024-09-30−$0.20 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-10, accession 0001493152-25-021496.Report this figurenot reported(0.07)Basic EPS, Q1 FY2025, three months to 2025-03-31−$0.07 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-14, accession 0001493152-26-023010.Report this figure(0.17)Basic EPS, Q2 FY2025, three months to 2025-06-30−$0.17 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-13, accession 0001493152-26-037854.Report this figure(0.03)Basic EPS, Q3 FY2025, three months to 2025-09-30−$0.03 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-10, accession 0001493152-25-021496.Report this figurenot reported(0.03)Basic EPS, Q1 FY2026, three months to 2026-03-31−$0.03 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-14, accession 0001493152-26-023010.Report this figure(0.79)Basic EPS, Q2 FY2026, three months to 2026-06-30−$0.79 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-13, accession 0001493152-26-037854.Report this figure

Balance sheet

Cash and equivalents$5.2m, Q2 FY2026
Shareholders' equity$5.0m, Q2 FY2026
Telomir Pharmaceuticals, Inc., balance sheet, quarterly
Line itemUnitperiod not labelled2023-09-30FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Cash and equivalents$knot reported1.2Cash and equivalents, FY2023, at 2023-12-31$1.2k. XBRL concept us-gaap:Cash. 10-K filed 2025-02-04, accession 0001493152-25-004872.Report this figure3,274Cash and equivalents, Q1 FY2024, at 2024-03-31$3.3m. XBRL concept us-gaap:Cash. 10-Q filed 2024-05-13, accession 0001493152-24-018909.Report this figure1,884Cash and equivalents, Q2 FY2024, at 2024-06-30$1.9m. XBRL concept us-gaap:Cash. 10-Q filed 2024-08-13, accession 0001493152-24-031606.Report this figure835Cash and equivalents, Q3 FY2024, at 2024-09-30$834.6k. XBRL concept us-gaap:Cash. 10-Q filed 2024-11-12, accession 0001493152-24-044749.Report this figure1,266Cash and equivalents, FY2024, at 2024-12-31$1.3m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-08-14, accession 0001641172-25-023970.Report this figure403Cash and equivalents, Q1 FY2025, at 2025-03-31$403.0k. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-05-14, accession 0001641172-25-010298.Report this figure754Cash and equivalents, Q2 FY2025, at 2025-06-30$754.3k. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-08-14, accession 0001641172-25-023970.Report this figure7,329Cash and equivalents, Q3 FY2025, at 2025-09-30$7.3m. XBRL concept us-gaap:Cash. 10-Q filed 2025-11-10, accession 0001493152-25-021496.Report this figure7,287Cash and equivalents, FY2025, at 2025-12-31$7.3m. XBRL concept us-gaap:Cash. 10-Q filed 2026-08-13, accession 0001493152-26-037854.Report this figure5,561Cash and equivalents, Q1 FY2026, at 2026-03-31$5.6m. XBRL concept us-gaap:Cash. 10-Q filed 2026-05-14, accession 0001493152-26-023010.Report this figure5,170Cash and equivalents, Q2 FY2026, at 2026-06-30$5.2m. XBRL concept us-gaap:Cash. 10-Q filed 2026-08-13, accession 0001493152-26-037854.Report this figure
Current assets$knot reported435Current assets, FY2023, at 2023-12-31$435.2k. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2025-02-04, accession 0001493152-25-004872.Report this figure3,503Current assets, Q1 FY2024, at 2024-03-31$3.5m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-05-13, accession 0001493152-24-018909.Report this figure2,102Current assets, Q2 FY2024, at 2024-06-30$2.1m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-08-13, accession 0001493152-24-031606.Report this figure1,042Current assets, Q3 FY2024, at 2024-09-30$1.0m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-11-12, accession 0001493152-24-044749.Report this figure1,324Current assets, FY2024, at 2024-12-31$1.3m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2026-03-17, accession 0001493152-26-010625.Report this figure491Current assets, Q1 FY2025, at 2025-03-31$491.2k. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-05-14, accession 0001641172-25-010298.Report this figure830Current assets, Q2 FY2025, at 2025-06-30$829.6k. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-08-14, accession 0001641172-25-023970.Report this figure7,402Current assets, Q3 FY2025, at 2025-09-30$7.4m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-11-10, accession 0001493152-25-021496.Report this figure7,341Current assets, FY2025, at 2025-12-31$7.3m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-13, accession 0001493152-26-037854.Report this figure5,790Current assets, Q1 FY2026, at 2026-03-31$5.8m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-05-14, accession 0001493152-26-023010.Report this figure5,366Current assets, Q2 FY2026, at 2026-06-30$5.4m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-13, accession 0001493152-26-037854.Report this figure
Total assets$knot reported4,774Total assets, FY2023, at 2023-12-31$4.8m. XBRL concept us-gaap:Assets. 10-K filed 2025-02-04, accession 0001493152-25-004872.Report this figure3,503Total assets, Q1 FY2024, at 2024-03-31$3.5m. XBRL concept us-gaap:Assets. 10-Q filed 2024-05-13, accession 0001493152-24-018909.Report this figure2,102Total assets, Q2 FY2024, at 2024-06-30$2.1m. XBRL concept us-gaap:Assets. 10-Q filed 2024-08-13, accession 0001493152-24-031606.Report this figure1,042Total assets, Q3 FY2024, at 2024-09-30$1.0m. XBRL concept us-gaap:Assets. 10-Q filed 2024-11-12, accession 0001493152-24-044749.Report this figure1,324Total assets, FY2024, at 2024-12-31$1.3m. XBRL concept us-gaap:Assets. 10-K filed 2026-03-17, accession 0001493152-26-010625.Report this figure491Total assets, Q1 FY2025, at 2025-03-31$491.2k. XBRL concept us-gaap:Assets. 10-Q filed 2025-05-14, accession 0001641172-25-010298.Report this figure830Total assets, Q2 FY2025, at 2025-06-30$829.6k. XBRL concept us-gaap:Assets. 10-Q filed 2025-08-14, accession 0001641172-25-023970.Report this figure7,402Total assets, Q3 FY2025, at 2025-09-30$7.4m. XBRL concept us-gaap:Assets. 10-Q filed 2025-11-10, accession 0001493152-25-021496.Report this figure7,341Total assets, FY2025, at 2025-12-31$7.3m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-13, accession 0001493152-26-037854.Report this figure5,790Total assets, Q1 FY2026, at 2026-03-31$5.8m. XBRL concept us-gaap:Assets. 10-Q filed 2026-05-14, accession 0001493152-26-023010.Report this figure5,366Total assets, Q2 FY2026, at 2026-06-30$5.4m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-13, accession 0001493152-26-037854.Report this figure
Current liabilities$knot reported1,336Current liabilities, FY2023, at 2023-12-31$1.3m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2025-02-04, accession 0001493152-25-004872.Report this figure487Current liabilities, Q1 FY2024, at 2024-03-31$486.6k. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-05-13, accession 0001493152-24-018909.Report this figure534Current liabilities, Q2 FY2024, at 2024-06-30$534.2k. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-08-13, accession 0001493152-24-031606.Report this figure600Current liabilities, Q3 FY2024, at 2024-09-30$599.9k. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-11-12, accession 0001493152-24-044749.Report this figure681Current liabilities, FY2024, at 2024-12-31$681.0k. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2026-03-17, accession 0001493152-26-010625.Report this figure652Current liabilities, Q1 FY2025, at 2025-03-31$652.3k. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-05-14, accession 0001641172-25-010298.Report this figure348Current liabilities, Q2 FY2025, at 2025-06-30$348.4k. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-08-14, accession 0001641172-25-023970.Report this figure423Current liabilities, Q3 FY2025, at 2025-09-30$422.8k. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-11-10, accession 0001493152-25-021496.Report this figure1,428Current liabilities, FY2025, at 2025-12-31$1.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-13, accession 0001493152-26-037854.Report this figure827Current liabilities, Q1 FY2026, at 2026-03-31$827.3k. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-05-14, accession 0001493152-26-023010.Report this figure332Current liabilities, Q2 FY2026, at 2026-06-30$332.4k. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-13, accession 0001493152-26-037854.Report this figure
Total liabilities$knot reported1,336Total liabilities, FY2023, at 2023-12-31$1.3m. XBRL concept us-gaap:Liabilities. 10-K filed 2025-02-04, accession 0001493152-25-004872.Report this figure487Total liabilities, Q1 FY2024, at 2024-03-31$486.6k. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-05-13, accession 0001493152-24-018909.Report this figure534Total liabilities, Q2 FY2024, at 2024-06-30$534.2k. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-08-13, accession 0001493152-24-031606.Report this figure600Total liabilities, Q3 FY2024, at 2024-09-30$599.9k. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-11-12, accession 0001493152-24-044749.Report this figure681Total liabilities, FY2024, at 2024-12-31$681.0k. XBRL concept us-gaap:Liabilities. 10-K filed 2026-03-17, accession 0001493152-26-010625.Report this figure652Total liabilities, Q1 FY2025, at 2025-03-31$652.3k. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-05-14, accession 0001641172-25-010298.Report this figure348Total liabilities, Q2 FY2025, at 2025-06-30$348.4k. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-08-14, accession 0001641172-25-023970.Report this figure423Total liabilities, Q3 FY2025, at 2025-09-30$422.8k. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-11-10, accession 0001493152-25-021496.Report this figure1,428Total liabilities, FY2025, at 2025-12-31$1.4m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-13, accession 0001493152-26-037854.Report this figure827Total liabilities, Q1 FY2026, at 2026-03-31$827.3k. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-05-14, accession 0001493152-26-023010.Report this figure332Total liabilities, Q2 FY2026, at 2026-06-30$332.4k. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-13, accession 0001493152-26-037854.Report this figure
Shareholders' equity$k2,178Shareholders' equity, period not labelled, at 2023-09-30$2.2m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2024-11-12, accession 0001493152-24-044749.Report this figure3,438Shareholders' equity, FY2023, at 2023-12-31$3.4m. XBRL concept us-gaap:StockholdersEquity. 10-K filed 2026-03-17, accession 0001493152-26-010625.Report this figure3,017Shareholders' equity, Q1 FY2024, at 2024-03-31$3.0m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-10, accession 0001493152-25-021496.Report this figure1,628Shareholders' equity, Q2 FY2024, at 2024-06-30$1.6m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-10, accession 0001493152-25-021496.Report this figure442Shareholders' equity, Q3 FY2024, at 2024-09-30$442.1k. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-10, accession 0001493152-25-021496.Report this figure643Shareholders' equity, FY2024, at 2024-12-31$643.0k. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-13, accession 0001493152-26-037854.Report this figure(161)Shareholders' equity, Q1 FY2025, at 2025-03-31−$161.1k. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-13, accession 0001493152-26-037854.Report this figure481Shareholders' equity, Q2 FY2025, at 2025-06-30$481.2k. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-13, accession 0001493152-26-037854.Report this figure6,979Shareholders' equity, Q3 FY2025, at 2025-09-30$7.0m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-10, accession 0001493152-25-021496.Report this figure5,913Shareholders' equity, FY2025, at 2025-12-31$5.9m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-13, accession 0001493152-26-037854.Report this figure4,962Shareholders' equity, Q1 FY2026, at 2026-03-31$5.0m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-13, accession 0001493152-26-037854.Report this figure5,033Shareholders' equity, Q2 FY2026, at 2026-06-30$5.0m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-13, accession 0001493152-26-037854.Report this figure

Cash flow

Operating cash flow−$1.0m, Q2 FY2026
Telomir Pharmaceuticals, Inc., cash flow, quarterly
Line itemUnitperiod not labelled2023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Operating cash flow$k(2,003)Operating cash flow, period not labelled, three months to 2023-09-30−$2.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2024-11-12, accession 0001493152-24-044749. Derived: 9-month figure less the 6-month figure.Report this figure(1,087)Operating cash flow, Q4 FY2023, three months to 2023-12-31−$1.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-02-04, accession 0001493152-25-004872. Derived: 12-month figure less the 9-month figure.Report this figure(1,939)Operating cash flow, Q1 FY2024, three months to 2024-03-31−$1.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-05-14, accession 0001641172-25-010298.Report this figure(1,523)Operating cash flow, Q2 FY2024, three months to 2024-06-30−$1.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-08-14, accession 0001641172-25-023970. Derived: 6-month figure less the 3-month figure.Report this figure(1,002)Operating cash flow, Q3 FY2024, three months to 2024-09-30−$1.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-10, accession 0001493152-25-021496. Derived: 9-month figure less the 6-month figure.Report this figure(606)Operating cash flow, Q4 FY2024, three months to 2024-12-31−$605.8k. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-17, accession 0001493152-26-010625. Derived: 12-month figure less the 9-month figure.Report this figure(863)Operating cash flow, Q1 FY2025, three months to 2025-03-31−$863.1k. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-14, accession 0001493152-26-023010.Report this figure(696)Operating cash flow, Q2 FY2025, three months to 2025-06-30−$696.4k. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-13, accession 0001493152-26-037854. Derived: 6-month figure less the 3-month figure.Report this figure(927)Operating cash flow, Q3 FY2025, three months to 2025-09-30−$927.3k. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-10, accession 0001493152-25-021496. Derived: 9-month figure less the 6-month figure.Report this figure(1,201)Operating cash flow, Q4 FY2025, three months to 2025-12-31−$1.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-17, accession 0001493152-26-010625. Derived: 12-month figure less the 9-month figure.Report this figure(1,774)Operating cash flow, Q1 FY2026, three months to 2026-03-31−$1.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-14, accession 0001493152-26-023010.Report this figure(1,012)Operating cash flow, Q2 FY2026, three months to 2026-06-30−$1.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-13, accession 0001493152-26-037854. Derived: 6-month figure less the 3-month figure.Report this figure

Shares

Diluted shares (weighted)60.84m, Q2 FY2026
Telomir Pharmaceuticals, Inc., shares, quarterly
Line itemUnitperiod not labelled2023-03-31period not labelled2023-06-30period not labelled2023-09-30Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q1 FY20262026-03-31Q2 FY20262026-06-30
Diluted shares (weighted)m shares26.9Diluted shares (weighted), period not labelled, three months to 2023-03-3126,893,014 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-05-13, accession 0001493152-24-018909.Report this figure27.1Diluted shares (weighted), period not labelled, three months to 2023-06-3027,097,294 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-08-13, accession 0001493152-24-031606.Report this figure27.1Diluted shares (weighted), period not labelled, three months to 2023-09-3027,097,294 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-11-12, accession 0001493152-24-044749.Report this figure29.3Diluted shares (weighted), Q1 FY2024, three months to 2024-03-3129,276,481 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-05-14, accession 0001641172-25-010298.Report this figure29.6Diluted shares (weighted), Q2 FY2024, three months to 2024-06-3029,609,814 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-08-14, accession 0001641172-25-023970.Report this figure29.6Diluted shares (weighted), Q3 FY2024, three months to 2024-09-3029,609,814 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-10, accession 0001493152-25-021496.Report this figure29.8Diluted shares (weighted), Q1 FY2025, three months to 2025-03-3129,762,671 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-14, accession 0001493152-26-023010.Report this figure30.0Diluted shares (weighted), Q2 FY2025, three months to 2025-06-3030,010,165 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-13, accession 0001493152-26-037854.Report this figure32.4Diluted shares (weighted), Q3 FY2025, three months to 2025-09-3032,398,906 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-10, accession 0001493152-25-021496.Report this figure34.4Diluted shares (weighted), Q1 FY2026, three months to 2026-03-3134,380,971 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-14, accession 0001493152-26-023010.Report this figure60.8Diluted shares (weighted), Q2 FY2026, three months to 2026-06-3060,837,460 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-13, accession 0001493152-26-037854.Report this figure

Shares outstanding: 68.77mShares outstanding, period not labelled, at 2026-08-1268,774,956 shares. XBRL concept dei:EntityCommonStockSharesOutstanding. 10-Q filed 2026-08-13, accession 0001493152-26-037854.Report this figure at Aug 12, 2026, from the cover of the 10-Q filed Aug 13, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:50 ET. Listed shows no prices and gives no investment advice.